Receptor Targeting Nanobodies: Locking the Door for All MERS-CoV Mutations as a Novel Therapeutic Approach
ISEF · 2024 Translational Medical Science Third Award
Overview
The MERS-CoV is a critical public health concern due to its infectious nature, severe symptoms and high fatality rate, with 36% of MERS-CoV cases resulting in death. This highlights the urgent need to develop therapeutic antibody solutions to combat the ongoing MERS-CoV epidemic. Anti-MERS-CoV neutralizing antibodies are not effective in neutralizing MERS-CoV due to the consistent mutations resulting in neutralization-escaping variants, which presents a significant gap in tackling the MERS-CoV epidemic. This project proposes an innovative approach to block MERS-CoV viral infection, by targeting the gateway receptor of MERS-CoV, named dipeptidyl peptidase 4 (DPP4) receptor. This approach employs monoclonal nanobody (Nb) Fc-fusion proteins to specifically block DPP4 receptors and inherently prevent the entry of all MERS-CoV variants. Using Artificial Intelligence-derived antibody CDR dissection and analysis algorithms, five Nbs with different attributes and key amino acid sequences were designed through in silico docking, 3-Dimensional homology, and local energy minimization. The resultant Nbs were produced in our lab and their neutralization capacity was tested through multiple in vitro assays including MERS-CoV pseudovirus Micro-Neutralization Test and cell-based binding assays. Our results demonstrated that four out of the five anti-DPP4 Nbs' designs were able to successfully bind to DPP4 and inherently inhibit MERS-CoV pseudotyped virus, with one candidate (Nb-212) showing the highest readings in all validation assays. These results support the utility of 3D-designed receptor-targeting nanobody Fc-fusion proteins to develop a universal immunotherapy to combat MERS-CoV infection, despite the mutable nature of the virus.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2023
Development of Universal Multi-Target Antibody-Like Vaccines Against the Highly Pathogenic Coronaviruses
ISEF · 2022
De Novo Nanobody Design With Neural Networks, AlphaFold, and Docking Algorithms
ISEF · 2022
Predicting Virus-Human Interactions To Facilitate the Design of Anti-Coronavirus Vaccines and Therapeutics
ISEF · 2026
De novo Design of Broadly Neutralizing Antibodies for Rapidly Evolving Pathogens
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair